Seminars in Nuclear Medicine
Volume 32, Issue 4 , Pages 240-271 , October 2002

Positron emission tomography in lung cancer

  • I. Ho Shon

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Ivan Ho Shon, FRACP, Clinical Ultrasound and Nuclear Medicine, Liverpool Health Service, PO Box 7103, Liverpool BC, New South Wales 2170, Australia.
    • ,
  • M.J. O'Doherty
    • ,
  • M.N. Maisey

References 

  1. Quinn MJ, Babb PJ, Brock A, et al. In: Cancer Trends in England and Wales, 1950–1999. Studies in Medical and Population Subjects No. 66. London, UK: The Stationery Office; 2001;
  2. -1998, Available at Ries L, Eisner M, Kosary C, et al. Bethesda, MD, National Cancer Institute, 2001 SEER Cancer Statistics Review. 1973;
  3. Ginsberg R, Evertt E, Rosenzweig K. Non-small cell lung cancer. In: DeVita V, Hellman S, Rosenberg S editor. Cancer: Principles and Practice of Oncology. vol 1:Philadelphia, PA: Lippincott Williams and Wilkins; 2001;p. 925–983
  4. Murren J, Glatstein E, Pass H. Small cell lung cancer. In: DeVita V, Hellman S, Rosenberg S editor. Cancer: Principles and Practice of Oncology. vol 1:Philadelphia, PA: Lippincott Williams and Wilkins; 2001;p. 983–1018
  5. Mountain CF. Revisions in the international system for staging lung cancer. Chest. 1997;111:1710–1717
  6. Chiti A, Schreiner FA, Crippa F, et al. Nuclear medicine procedures in lung cancer. Eur J Nucl Med. 1999;26:533–555
  7. Abdel-Dayem HM, Scott A, Macapinlac H, et al. Tracer imaging in lung cancer. Eur J Nucl Med. 1994;21:57–81
  8. DeMeester TR, Bekerman C, Joseph JG, et al. Gallium-67 scanning for carcinoma of the lung. J Thorac Cardiovasc Surg. 1976;72:699–708
  9. Buccheri G, Vola F, Ferrigno D, et al. Yield of total body Ga-67 scintigraphy in the staging of non-small cell lung cancer. Tumori. 1989;75:38–42
  10. Kashitani N, Makihara S, Maeda T, et al. Thallium-201-chloride and technetium-99m-MIBI SPECT of primary and metastatic lung carcinoma. Oncol Rep. 1999;6:127–133
  11. Ikeda E, Taki L, Kinuya S, et al. Thallium-201 SPECT with triple-headed gamma camera for differential diagnosis of small pulmonary nodular lesion 20 mm in diameter or smaller. Ann Nucl Med. 2000;14:91–95
  12. Ishibashi M, Fujii T, Yamana H, et al. Relationship between cancer cell proliferation and thallium-201 uptake in lung cancer. Ann Nucl Med. 2000;14:255–261
  13. Takekawa H, Takaoka K, Tsukamoto E, et al. Thallium-201 single photon emission computed tomography as an indicator of prognosis for patients with lung carcinoma. Cancer. 1997;80:198–203
  14. Suga K, Kume N, Nishigauchi K, et al. 201T1 SPECT as in indicator for early prediction of therapeutic effects in patients with non-small cell lung cancer. Ann Nucl Med. 1998;12:355–362
  15. Higashi K, Nishikawa T, Seki H, et al. Comparison of fluorine-18-FDG PET and thallium-201 SPECT in evaluation of lung cancer. J Nucl Med. 1998;39:9–15
  16. Higashi K, Ueda Y, Sakuma T, et al. Comparison of [(18)F]FDG PET and (201)T1 SPECT in evaluation of pulmonary nodules. J Nucl Med. 2001;42:1489–1496
  17. Yamamoto Y, Nishiyama Y, Satoh K, et al. Comparative evaluation of Tc-99m MIBI and T1-201 chloride SPECT in non-small-cell lung cancer mediastinal lymph node metastases. Clin Nucl Med. 2000;25:29–32
  18. Tonami N, Shuke N, Yokoyama K, et al. Thallium-201 single photon emission computed tomography in the evaluation of suspected lung cancer. J Nucl Med. 1989;30:997–1004
  19. Hassan IM, Sahweil A, Constantinides C, et al. Uptake and kinetics of Tc-99m hexakis 2-methoxy isobutyl isonitrile in benign and malignant lesions in the lungs. Clin Nucl Med. 1989;14:333–340
  20. Kao CH, Wang SJ, Lin WY, et al. Differentiation of single solid lesions in the lungs by means of single-photon emission tomography with technetium-99m methoxyisobutylisonitrile. Eur J Nucl Med. 1993;20:249–254
  21. Wang H, Maurea S, Mainolfi C, et al. Tc-99m MIBI scintigraphy in patients with lung cancer. Comparison with CT and fluorine-18 FDG PET imaging. Clin Nucl Med. 1997;22:243–249
  22. Tanaka S, Asao T, Ubukata M, et al. Effectiveness of Tc-99m MIBI scintigraphy in diagnosing lung cancer. Surg Today. 1997;27:623–626
  23. Minai OA, Raja S, Mehta AC, et al. Role of Tc-99m MIBI in the evaluation of single pulmonary nodules: A preliminary report. Thorax. 2000;55:60–62
  24. Shiau YC, Hsieh JF, Tsai SC, et al. Technetium-99m methoxyisobutyl-isonitrile chest single photon emission computed tomography to detect mediastinal lymph node metastasis in patients with non-small cell lung cancer: Comparison with computed tomography. Anticancer Res. 2000;20:3751–3754
  25. Kostakoglu L, Kiratli P, Ruacan S, et al. Association of tumor washout rates and accumulation of technetium-99m-MIBI with expression of P-glycoprotein in lung cancer. J Nucl Med. 1998;39:228–234
  26. Kao CH, Hsieh JF, Tsai SC, et al. Quickly predicting chemotherapy response to paclitaxel-based therapy in non-small cell lung cancer by early technetium-99m methoxyisobutylisonitrile chest single-photon-emission computed tomography. Clin Cancer Res. 2000;6:820–824
  27. Nishiyama Y, Yamamoto Y, Satoh K, et al. Comparative study of Tc-99m MIBI and T1-201 SPECT in predicting chemotherapeutic response in non-small-cell lung cancer. Clin Nucl Med. 2000;25:364–369
  28. Atasever T, Gokcora N, Vural G, et al. Evaluation of malignant and benign lung lesions with 99Tcm-tetrofosmin. Nucl Med Commun. 1996;17:577–582
  29. Kao CH, ChangLai SP, Shen YY, et al. Technetium-99m-tetrofosmin SPECT imaging of lung masses: A negative study. J Nucl Med. 1997;38:1015–1019
  30. Schillaci O, Monteleone F, D'Andrea N, et al. Technetium-99m tetrofosmin single photon emission computed tomography in the evaluation of suspected lung cancer. Cancer Biother Radiopharm. 1999;14:129–134
  31. Tatsumi M, Yutani K, Nishimura T. Evaluation of lung cancer by 99mTc-tetrofosmin SPECT: Comparison with [18F]FDG-PET. J Comput Assist Tomogr. 2000;24:574–580
  32. O'Byrne KJ, Carney DN. Somatostatin and the lung. Lung Cancer. 1993;10:151–172
  33. Reisinger I, Bohuslavitzki KH, Brenner W, et al. Somatostatin receptor scintigraphy in small-cell lung cancer: Results of a multicenter study. J Nucl Med. 1998;39:224–227
  34. Reubi JC, Waser B, Sheppard M, et al. Somatostatin receptors are present in small-cell but not in non-small-cell primary lung carcinomas: Relationship to EGF-receptors. Int J Cancer. 1990;45:269–274
  35. Blum J, Handmaker H, Lister-James J, et al. A multicenter trial with a somatostatin analog (99m)Tc depreotide in the evaluation of solitary pulmonary nodules. Chest. 2000;117:1232–1238
  36. Warburg O. In: The Metabolism of Tumors. London, UK: Constable; 1930;p. 129–169
  37. Isselbacher KJ. Increased uptake of amino acids and 2-deoxy-d-glucose by virus-transformed cells in culture. In: Proc Natl Acad Sci U S A. 69:1972;p. 585–589
  38. Lai MH, Weber G. Increased concentration of thymidine kinase in rat hepatomas. Biochem Biophys Res Commun. 1983;111:280–287
  39. Gronowitz JS, Hagberg H, Kallander CF, et al. The use of serum deoxythymidine kinase as a prognostic marker, and in the monitoring of patients with non-Hodgkin's lymphoma. Br J Cancer. 1983;47:487–495
  40. Bello LJ. Regulation of thymidine kinase synthesis in human cells. Exp Ecll Res. 1974;89:263–274
  41. Thorens B. Glucose transporters in the regulation of intestinal, renal, and liver glucose fluxes. Am J Physiol. 1996;270:G541–G553
  42. Gallagher BM, Fowler JS, Gutterson NI, et al. Metabolic trapping as a principle of oradiopharmaceutical design: Some factors responsible for the biodistribution of [18F] 2-deoxy-2-fluoro-d-glucose. J Nucl Med. 1978;19:1154–1161
  43. Smith TA. FDG uptake, tumour characteristics and response to therapy: A review. Nucl Med Commun. 1998;19:97–105
  44. Mueckler M. Facilitative glucose transporters. Eur J Biochem. 1994;219:713–725
  45. Yamamoto T, Seino Y, Fukumoto H, et al. Over-expression of facilitative glucose transporter genes in human cancer. Biochem Biophys Res Commun. 1990;170:223–230
  46. Brown RS, Leung JY, Kison PV, et al. Glucose transporters and FDG uptake in untreated primary human non-small cell lung cancer. J Nucl Med. 1999;40:556–565
  47. Higashi K, Ueda Y, Sakurai A, et al. Correlation of Glut-1 glucose transporter expression with [18F]FDG uptake in non-small cell lung cancer. Eur J Nucl Med. 2000;27:1778–1785
  48. Marom EM, Aloia TA, Moore MB, et al. Correlation of FDG-PET imaging with Glut-1 and Glut-3 expression in early-stage non-small cell lung cancer. Lung Cancer. 2001;33:99–107
  49. Hallett WA, Marsden PK, Cronin BF, et al. Effect of corrections for blood glucose and body size on [18F]FDG PET standardised uptake values in lung cancer. Eur J Nucl Med. 2001;228:919–922
  50. Wong CY, Nunez R, Bohdiewicz P, et al. Patterns of abnormal FDG uptake by various histological types of non-small cell lung cancer at initial staging by PET. Eur J Nucl Med. 2001;28:1702–1705
  51. Midthun DE, Swensen SJ, Jett JR. Approach to the solitary pulmonary nodule. In: Mayo Clin Proc. 68:1993;p. 378–385
  52. Lillington GA. Management of the solitary pulmonary nodule. Hosp Pract (Off Ed). 1993;28:41–48
  53. Zerhouni EA, Stitik FP, Siegelman SS, et al. CT of the pulmonary nodule: A cooperative study. Radiology. 1986;160:319–327
  54. Shulkin AN. Management of the indeterminate solitary pulmonary nodule: A pulmonologist's view. Ann Thorac Surg. 1993;56:743–744
  55. Swensen SJ, Viggiano RW, Midthun DE, et al. Lung nodule enhancement at CT: Multicenter study. Radiology. 2000;214:73–80
  56. Viggiano RW, Swensen SJ, Rosenow EC. Evaluation and management of solitary and multiple pulmonary nodules. Clin Chest Med. 1992;13:83–95
  57. Gould MK, Maclean CC, Kuschner WG, et al. Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: A meta-analysis. JAMA. 2001;285:914–924
  58. Cummings SR, Lillington GA, Richard RJ. Managing solitary pulmonary nodules. The choice of strategy is a “close call”. Am Rev Respir Dis. 1986;134:453–460
  59. Swanson SJ, Jaklitsch MT, Mentzer SJ, et al. Management of the solitary pulmonary nodule: Role of thoracoscopy in diagnosis and therapy. Chest. 1999;116:523S–524S
  60. Khouri NF, Meziane MA, Zerhouni EA, et al. The solitary pulmonary nodule. Assessment, diagnosis, and management. Chest. 1987;91:128–133
  61. Erasmus JJ, Connolly JE, McAdams HP, et al. Solitary pulmonary nodules: Part I. Morphologic evaluation for differentiation of benign and malignant lesions. Radiographics. 2000;20:43–58
  62. Midthun DE. Solitary pulmonary nodule: Time to think small. Curr Opin Pulm Med. 2000;6:364–370
  63. Siegelman SS, Khouri NF, Leo FP, et al. Solitary pulmonary nodules: CT assessment. Radiology. 1986;160:307–312
  64. Bhalla M, Shepard JA, Nakamura K, et al. Dual kV CT to detect calcification in solitary pulmonary nodule. J Comput Assist Tomogr. 1995;19:44–47
  65. Shaffer K. Role of radiology for imaging and biopsy of solitary pulmonary nodules. Chest. 1999;116:519S–522S
  66. Kono M, Adachi S, Kusumoto M, et al. Clinical utility of Gd-DTPA-enhanced magnetic resonance imaging in lung cancer. J Thorac Imaging. 1993;8:18–26
  67. Kauczor HU, Kreitner KF. Contrast-enhanced MRI of the lung. Eur J Radiol. 2000;34:196–207
  68. Lillington GA. Management of solitary pulmonary nodules. How to decide when resection is required. Postgrad Med. 1997;101:145–150
  69. Lillington GA. Solitary pulmonary nodules: New wine in old bottles. Curr Opin Pulm Med. 2001;7:242–246
  70. Yankelevitz DF, Henschke CI. Does 2-year stability imply that pulmonary nodules are benign?. AJR Am J Roentgenol. 1997;168:325–328
  71. Erasmus JJ, McAdams HP, Connolly JE. Solitary pulmonary nodules: Part II. Evaluation of the indeterminate nodule. Radiographics. 2000;20:59–66
  72. Chechani V. Bronchoscopic diagnosis of solitary pulmonary nodules and lung masses in the absence of endobronchial abnormality. Chest. 1996;109:620–625
  73. Naidich DP, Sussman R, Kutcher WL, et al. Solitary pulmonary nodules. CT-bronchoscopic correlation. Chest. 1988;93:595–598
  74. Salathe M, Soler M, Bolliger CT, et al. Transbronchial needle aspiration in routine fiberoptic bronchoscopy. Respiration. 1992;59:5–8
  75. Wallace JM, Deutsch AL. Flexible fiberoptic bronchoscopy and percutaneous needle lung aspiration for evaluating the solitary pulmonary nodule. Chest. 1982;81:665–671
  76. Cortese DA, McDougall JC. Biopsy and brushing of peripheral lung cancer with fluoroscopic guidance. Chest. 1979;75:141–145
  77. Yankelevitz DF, Henschke CI, Koizumi J, et al. CT-guided transthoracic needle biopsy following indeterminate fiberoptic bronchoscopy in solitary pulmonary nodules. Clin Imaging. 1998;22:7–10
  78. Berquist TH, Bailey PB, Cortese DA, et al. Transthoracic needle biopsy: Accuracy and complications in relation to location and type of lesion. In: Mayo Clin Proc. 55:1980;p. 475–481
  79. Levine MS, Weiss JM, Harrell JH, et al. Transthoracic needle aspiration biopsy following negative fiberoptic bronchoscopy in solitary pulmonary nodules. Chest. 1988;93:1152–1155
  80. Klein JS, Zarka MA. Transthoracic needle biopsy: An overview. J Thorac Imaging. 1997;12:232–249
  81. Fink I, Gamsu G, Harter LP. CT-guided aspiration biopsy of the thorax. J Comput Assist Tomogr. 1982;6:958–962
  82. Khouri NF, Stitik FP, Erozan YS, et al. Transthoracic needle aspiration biopsy of benign and malignant lung lesions. AJR Am J Roentgenol. 1985;144:281–288
  83. Westcott JL. Direct percutaneous needle aspiration of localized pulmonary lesions: Result in 422 patients. Radiology. 1980;137:31–35
  84. Calhoun P, Feldman PS, Armstrong P, et al. The clinical outcome of needle aspirations of the lung when cancer is not diagnosed. Ann Thorac Surg. 1986;41:592–596
  85. Austin JH, Cohen MB. Value of having a cytopathologist present during percutaneous fine-needle aspiration biopsy of lung: Report of 55 cancer patients and metaanalysis of the literature. AJR Am J Roentgenol. 1993;160:175–177
  86. Dewan NA, Reeb SD, Gupta NC, et al. PET-FDG imaging and transthoracic needle lung aspiration biopsy in evaluation of pulmonary lesions. A comparative risk-benefit analysis. Chest. 1995;108:441–446
  87. Larscheid RC, Thorpe PE, Scott WJ. Percutaneous transthoracic needle aspiration biopsy: A comprehensive review of its current role in the diagnosis and treatment of lung tumors. Chest. 1998;114:704–709
  88. Klein JS, Salomon G, Stewart EA. Transthoracic needle biopsy with a coaxially placed 20-gauge automated cutting needle: Results in 122 patients. Radiology. 1996;198:715–720
  89. Westcott JL. Percutaneous transthoracic needle biopsy. Radiology. 1988;169:593–601
  90. Mack MJ, Hazelrigg SR, Landreneau RJ, et al. Thoracoscopy for the diagnosis of the indeterminate solitary pulmonary nodule. Ann Thorac Surg. 1993;56:825–830
  91. Mack MJ, Aronoff RJ, Acuff TE, et al. Present role of thoracoscopy in the diagnosis and treatment of diseases of the chest. Ann Thorac Surg. 1992;54:403–408
  92. Mitruka S, Landreneau RJ, Mack MJ, et al. Diagnosing the indeterminate pulmonary nodule: Percutaneous biopsy versus thoracoscopy. Surgery. 1995;118:676–684
  93. Landreneau RJ, Hazelrigg SR, Ferson PF, et al. Thoracoscopic resection of 85 pulmonary lesions. Ann Thorac Surg. 1992;54:415–419
  94. Allen MS, Deschamps C, Lee RE, et al. Video-assisted thoracoscopic stapled wedge excision for indeterminate pulmonary nodules. J Thorac Cardiovasc Surg. 1993;106:1048–1052
  95. Kubota K, Matsuzawa T, Fujiwara T, et al. Differential diagnosis of lung tumor with positron emission tomography: A prospective study. J Nucl Med. 1990;31:1927–1932
  96. Knight SB, Delbeke D, Stewart JR, et al. Evaluation of pulmonary lesions with FDG-PET. Comparison of findings in patients with and without a history of prior malignancy. Chest. 1996;109:982–988
  97. Patz EF, Lowe VJ, Hoffman JM, et al. Focal pulmonary abnormalities: Evaluation with F-18 fluorodeoxyglucose PET scanning. Radiology. 1993;188:487–490
  98. Duhaylongsod FG, Lowe VJ, Patz EF, et al. Detection of primary and recurrent lung cancer by means of F-18 fluorodeoxyglucose positron emission tomography (FDG PET). J Thorac Cardiovasc Surg. 1995;110:130–139
  99. Duhayloongsod FG, Lowe VJ, Patz EF, et al. Lung tumor growth correlates with glucose metabolism measured by fluoride-18 fluorodeoxyglucose positron emission tomography. Ann Thorac Surg. 1995;60:1348–1352
  100. Lowe VJ, Fletcher JW, Gobar L, et al. Prospective investigation of positron emission tomography in lung nodules. J Clin Oncol. 1998;16:1075–1084
  101. Saunders CA, Dussek JE, O'Doherty MJ, et al. Evaluation of fluorine-18-fluorodeoxyglucose whole body positron emission tomography imaging in the staging of lung cancer. Ann Thorac Surg. 1999;67:790–797
  102. Lowe VJ, Duhaylongsod FG, Patz EF, et al. Pulmonary abnormalities and PET data analysis: A retrospective study. Radiology. 1997;202:435–439
  103. Lowe VJ, Hoffman JM, DeLong DM, et al. Semiquantitative and visual analysis of FDG-PET images in pulmonary abnormalities. J Nucl Med. 1994;35:1771–1776
  104. Gupta N, Gill H, Graeber G, et al. Dynamic positron emission tomography with F-18 fluorodeoxyglucose imaging in differentiation of benign from malignant lung/mediastinal lesions. Chest. 1998;114:1105–1111
  105. Hubner KF, Buonocore E, Gould HR, et al: Differentiating benign from malignant lung lesions using “quantitative” parameters of FDG PET images Clin Nucl Med 21: 941–949
  106. Bakheet SM, Powe J. Benign causes of 18-FDG uptake on whole body imaging. In: Semin Nucl Med. 28:1998;p. 352–358
  107. Slosman DO, Spiliopoulos A, Keller A, et al. Quantitative metabolic PET imaging of a plasma cell granuloma. J Thorac Imaging. 1994;9:116–119
  108. Bousson V, Moretti JL, Weinmann P, et al. Assessment of malignancy in pulmonary lesions: FDG dual-head coincidence gamma camera imaging in association with serum tumor marker measurement. J Nucl Med. 2000;41:1801–1807
  109. Hoffman EJ, Huang SC, Phelps ME. Quantitation in positron emission computed tomography: 1. Effect of object size. J Comput Assist Tomogr. 1979;3:299–308
  110. Graeber GM, Gupta NC, Murray GF. Positron emission tomographic imaging with fluorodeoxyglucose is efficacious in evaluating malignant pulmonary disease. J Thorac Cardiovasc Surg. 1999;117:719–727
  111. Avril N, Bense S, Ziegler SI, et al. Breast imaging with fluorine-18-FDG PET: Quantitative image analysis. J Nucl Med. 1997;38:1186–1191
  112. Dewan NA, Shehan CJ, Reeb SD, et al. Likelihood of malignancy in a solitary pulmonary nodule: Comparison of Bayesian analysis and results of FDG-PET scan. Chest. 1997;112:416–422
  113. Dewan NA, Gupta NC, Redepenning LS, et al. Diagnostic efficacy of PET-FDG imaging in solitary pulmonary nodules. Potential role in evaluation and management. Chest. 1993;104:997–1002
  114. Gupta NC, Maloof J, Gunel E. Probability of malignancy in solitary pulmonary nodules using fluorine-18-FDG and PET. J Nucl Med. 1996;37:943–948
  115. Gupta NC, Frank AR, Dewan NA, et al. Solitary pulmonary nodules: Detection of malignancy with PET with 2-[F-18]-fluoro-2-deoxy-d-glucose. Radiology. 1992;184:441–444
  116. Imdahl A, Jenkner S, Brink I, et al. Validation of FDG positron emission tomography for differentiation of unknown pulmonary lesions. Eur J Cardiothorac Surg. 2001;20:324–329
  117. Rege SD, Hoh CK, Glaspy JA, et al. Imaging of pulmonary mass lesions with whole-body positron emission tomography and fluorodeoxyglucose. Cancer. 1993;72:82–90
  118. Slosman DO, Spiliopoulos A, Couson F, et al. Satellite PET and lung cancer: A prospective study in surgical patients. Nucl Med Commun. 1993;14:955–961
  119. (abstr) Yap CS, Schiepers C, Fishbein M, et al. Metabolic imaging in lung cancer: How sensitive is it for bronchiolo-alveolar carcinoma?. Nucl Med. 2001;42:74|P
  120. (abstr) Hellwig D, Ukena D, Sybrecht GW, et al. FDG-PET for detection and staging of bronchioloalveolar carcinoma. J Nucl Med. 2001;42:74|P
  121. Prauer HW, Weber WA, Romer W, et al. Controlled prospective study of positron emission tomography using the glucose analogue [18f]fluorodeoxyglucose in the evaluation of pulmonary nodules. Br J Surg. 1998;85:1506–1511
  122. Lucas JD, O'Doherty MJ, Wong JC, et al. Evaluation of fluorodeoxyglucose positron emission tomography in the management of softtissue sarcomas. J Bone Joint Surg Br. 1998;80:441–447
  123. Hubner KF, Buonocore E, Singh SK, et al. Characterization of chest masses by FDG positron emission tomography. Clin Nucl Med. 1995;20:293–298
  124. Gambhir SS, Shepherd JE, Shah BD, et al. Analytical decision model for the cost-effective management of solitary pulmonary nodules. J Clin Oncol. 1998;16:2113–2125
  125. Dietlein M, Weber K, Gandjour A, et al. Cost-effectiveness of FDG-PET for the management of solitary pulmonary nodules: A decision analysis based on cost reimbursement in Germany. Eur J Nucl Med. 2000;27:1441–1456
  126. (abstr) Gould M, Sanders G, Barnett P, et al. Cost-effectiveness of positron emission tomography for diagnosis of solitary pulmonary nodules. Med Decis Making. 2001;21:528
  127. (abstr) Gould M, Sanders G, Maclean C, et al. Cost-effectiveness of alternative management strategies for patients with solitary pulmonary nodules. Am J Respir Crit Care Med. 2001;163:A72
  128. Caskey CI, Templeton PA, Zerhouni EA. Current evaluation of the solitary pulmonary nodule. Radiol Clin North Am. 1990;28:511–520
  129. Hain SF, Curran KM, Beggs AD, et al. PDG-PET as a “metabolic biopsy” tool in thoracic lesions with indeterminate biopsy. Eur J Nucl Med. 2001;28:1336–1340
  130. Tahara RW, Lackner RP, Graver LM. Is there a role for routine mediastinoscopy in patients with peripheral T1 lung cancers?. Am J Surg. 2000;180:488–491
  131. Feld R, Abratt R, Graziano S, et al. Pretreatment minimal staging and prognostic factors for non-small cell lung cancer. Lung Cancer. 1997;17(suppl 1):S3–S10
  132. Mountain CF, Dresler CM. Regional lymph node classification for lung cancer staging. Chest. 1997;111:1718–1723
  133. Maisey MN, Wahl RL, Barrington SF. In: Atlas of Clinical Positron Emission Tomography. London, UK: Arnold; 1999;
  134. Ginsberg RJ, Hill LD, Eagan RT, et al. Modern thirty-day operative mortality for surgical resections in lung cancer. J Thorac Cardiovasc Surg. 1983;86:654–658
  135. Vansteenkiste JF, De Leyn PR, Deneffe GJ, et al. Survival and prognostic factors in resected N2 non-small cell lung cancer: A study of 140 cases. Leuven Lung Cancer Group. Ann Thorac Surg. 1997;63:1441–1450
  136. Libshitz HI, McKenna RJ, Mountain CF. Patterns of mediastinal metastases in bronchogenic carcinoma. Chest. 1986;90:229–232
  137. Glazer GM, Gross BH, Quint LE, et al. Normal mediastinal lymph nodes: Number and size according to American Thoracic Society mapping. AJR Am J Roentgenol. 1985;144:261–265
  138. McLoud TC, Bourgouin PM, Greenberg RW, et al. Bronchogenic carcinoma: Analysis of staging in the mediastinum with CT by correlative lymph node mapping and sampling. Radiology. 1992;182:319–323
  139. Dales RE, Stark RM, Raman S. Computed tomography to stage lung cancer. Approaching a controversy using meta-analysis. Am Rev Respir Dis. 1990;141:1096–1101
  140. Dwamena BA, Sonnad SS, Angobaldo JO, et al. Metastases from non-small cell lung cancer: Mediastinal staging in the 1990s—meta-analytic comparison of PET and CT. Radiology. 1999;213:530–536
  141. BTS guidelines: Guidelines on the selection of patients with lung cancer for surgery. Thorax. 2001;56:89–108
  142. White PG, Adams H, Crane MD, et al. Preoperative staging of carcinoma of the bronchus: Can computed tomographic scanning reliably identify stage III tumours?. Thorax. 1994;49:951–957
  143. Patz EF, JJ Erasmus, McAdams HP, et al. Lung cancer staging and management: Comparison of contrast-enhanced and nonenhanced helical CT of the thorax. Radiology. 1999;212:56–60
  144. Oliver TW, Bernardino ME, Miller JI, et al. Isolated adrenal masses in nonsmall-cell bronchogenic carcinoma. Radiology. 1984;153:217–218
  145. ATS Guidelines. Pretreatment evaluation of non-small-cell lung cancer. The American Thoracic Society and The European Respiratory Society. Am J Respir Crit Care Med. 1997;156:320–333
  146. Patchell RA, Tibbs PA, Walsh JW, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med. 1990;322:494–500
  147. Silvestri GA, Littenberg B, Colice GL. The clinical evaluation for detecting metastatic lung cancer. A meta-analysis. Am J Respir Crit Care Med. 1995;152:225–230
  148. Hillers TK, Sauve MD, Guyatt GH. Analysis of published studies on the detection of extrathoracic metastases in patients presumed to have operable non-small cell lung cancer. Thorax. 1994;49:14–19
  149. Mentzer SJ, Swanson SJ, DeCamp MM, et al. Mediastinoscopy thoracoscopy, and video-assisted thoracic surgery in the diagnosis and staging of lung cancer. Chest. 1997;112:239S–241S
  150. Luke WP, Pearson FG, Todd TR, et al. Prospective evaluation of mediastinoscopy for assessment of carcinoma of the lung. J Thorac Cardiovasc Surg. 1986;91:53–56
  151. De Leyn P, Vansteenkiste J, Cuypers P, et al. Role of cervical mediastinoscopy in staging of non-small cell lung cancer without enlarged mediastinal lymph nodes on CT scan. Eur J Cardiothorac Surg. 1997;12:706–712
  152. Harrow EM, Abi-Saleh W, Blum J, et al. The utility of transbronchial needle aspiration in the staging of bronchogenic carcinoma. Am J Respir Crit Care Med. 2000;161:601–607
  153. Webb WR, Gatsonis C, Zerhouni EA, et al. CT and MR imaging in staging non-small cell bronchogenic carcinoma: Report of the Radiologic Diagnostic Oncology Group. Radiology. 1991;178:705–713
  154. Remer EM, Obuchowski N, Ellis JD, et al. Adrenal mass evaluation in patients with lung carcinomas: A cost-effectiveness analysis. AJR Am J Roentgenol. 2000;174:1033–1039
  155. Wahl RL, Quint LE, Greenough RL, et al. Staging of mediastinal non-small cell lung cancer with FDG PET, CT, and fusion images: Preliminary prospective evaluation. Radiology. 1994;191:371–377
  156. Lewis P, Griffin S, Marsden P, et al. Whole-body 18F-fluorodeoxyglucose positron emission tomography in preoperative evaluation of lung cancer. Lancet. 1994;344:1265–1266
  157. Scott WJ, Schwabe JL, Gupta NC, et al. Positron emission tomography of lung tumors and mediastinal lymph nodes using [18F]fluorodeoxyglucose. The Members of the PET-Lung Tumor Study Group. Ann Thorac Surg. 1994;58:698–703
  158. Reske SN, Kotzerke J. FDG-PET for clinical use: Results of the 3rd German Interdisciplinary Consensus Conference, “Onko-PET III”, 21 July and 19 September 2000. Eur J Nucl Med. 2001;28:1707–1723
  159. Fischer B, Mortensen J, Hojgaard L. Positron emission tomography in the diagnosis and staging of lung cancer: A systematic quantitative review. Lancet Oncol. 2001;2:659–666
  160. Vansteenkiste JF, Stroobants SG, De Leyn PR, et al. Lymph node staging in non-small-cell lung cancer with FDG-PET scan: A prospective study on 690 lymph node stations from 68 patients. J Clin Oncol. 1998;16:2142–2149
  161. Poncelet AJ, Lonneux M, Coche E, et al. PET-FDG scan enhances but does not replace preoperative surgical staging in non-small cell lung carcinoma. Eur J Cardiothorac Surg. 2001;20:468–474
  162. Scott WJ, Gobar LS, Terry LD, et al. Mediastinal lymph node staging of non-small-cell lung cancer: A prospective comparison of computed tomography and positron emission tomography. J Thorac Cardiovasc Surg. 1996;111:642–648
  163. Steinert HC, Hauser M, Allemann F, et al. Non-small cell lung cancer: Nodal staging with FDG PET versus CT with correlative lymph node mapping and sampling. Radiology. 1997;202:441–446
  164. Valk PE, Pounds TR, Hopkins DM, et al. Staging non-small cell lung cancer by whole-body positron emission tomographic imaging. Ann Thorac Surg. 1995;60:1573–1581
  165. Pieterman RM, van Putten JW, Meuzelaar JJ, et al. Preoperative staging of non-small-cell lung cancer with positron-emission tomography. N Engl J Med. 2000;43:254–261
  166. Farrell MA, McAdams HP, Herndon JE, et al. Non-small cell lung cancer: FDG PET for nodal staging in patients with stage I disease. Radiology. 2000;215:886–890
  167. Vansteenkiste JF, Stroobants SG, Dupont PJ, et al. FDG-PET scan in potentially operable non-small cell lung cancer: Do anatometabolic PET-CT fusion images improve the localisation of regional lymph node metastases? The Leuven Lung Cancer Group. Eur J Nucl Med. 1998;25:1495–1501
  168. Chin R, Ward R, Keyes JW, et al. Mediastinal staging of non-small-cell lung cancer with positron emission tomography. Am J Respir Crit Care Med. 1995;152:2090–2096
  169. Bury T, Paulus P, Dowlati A, et al. Staging of the mediastinum: Value of positron emission tomography imaging in non-small cell lung cancer. Eur Respir J. 1996;9:2560–2564
  170. Patz EF, Lowe VJ, Goodman PC, et al. Thoracic nodal staging with PET imaging with 18FDG in patients with bronchogenic carcinoma. Chest. 1995;108:1617–1621
  171. Berlangieri SU, Scott AM, Knight SR, et al. F-18 fluorodeoxyglucose positron emission tomography in the non-invasive staging of non-small cell lung cancer. Eur J Cardiothorac Surg. 1999;16(suppl 1):S25–S30
  172. Gupta NC, Graeber GM, Bishop HA. Comparative efficacy of positron emission tomography with fluorodeoxyglucose in evaluation of small (<1 cm), intermediate (1 to 3 cm), and large (>3 cm) lymph node lesions. Chest. 2000;117:773–778
  173. Dietlein M, Weber K, Gandjour A, et al. Cost-effectiveness of FDG-PET for the management of potentially operable non-small cell lung cancer: Priority for a PET-based strategy after nodal-negative CT results. Eur J Nucl Med. 2000;27:1598–1609
  174. Sasaki M, Ichiya Y, Kuwabara Y, et al. The usefulness of FDG positron emission tomography for the detection of mediastinal lymph node metastases in patients with non-small cell lung cancer: A comparative study with X-ray computed tomography. Eur J Nucl Med. 1996;23:741–747
  175. O'Doherty MJ, Marsden PK. Being equipped for clinical PET. Lancet. 2000;356:1701–1703
  176. Marom EM, McAdams HP, Erasmus JJ, et al. Staging non-small cell lung cancer with whole-body PET. Radiology. 1999;212:803–809
  177. Bury T, Dowlati A, Paulus P, et al. Whole-body 18FDG positron emission tomography in the staging of non-small cell lung cancer. Eur Respir J. 1997;10:2529–2534
  178. Quint LE, Tummala S, Brisson LJ, et al. Distribution of distant metastases from newly diagnosed non-small cell lung cancer. Ann Thorac Surg. 1996;62:246–250
  179. Larcos G, Maisey MN. FDG-PET screening for cerebral metastases in patients with suspected malignancy. Nucl Med Commun. 1996;17:197–198
  180. Griffeth LK, Rich KM, Dehdashti F, et al. Brain metastases from non-central nervous system tumors: Evaluation with PET. Radiology. 1993;186:37–44
  181. Cook GJ, Houston S, Rubens R, et al. Detection of bone metastases in breast cancer by 18FDG PET: Differing metabolic activity in osteoblastic and osteolytic lesions. J Clin Oncol. 1998;16:3375–3379
  182. Weder W, Schmid RA, Bruchhaus H, et al. Detection of extrathoracic metastases by positron emission tomography in lung cancer. Ann Thorac Surg. 1998;66:886–892
  183. Cook GJ, Maisey MN, Fogelman I. Fluorine-18-FDG PET in Paget's disease of bone. J Nucl Med. 1997;38:1495–1497
  184. Erasmus JJ, Patz EF, McAdams HP, et al. Evaluation of adrenal masses in patients with bronchogenic carcinoma using 18F-fluorodeoxyglucose positron emission tomography. AJR Am J Roentgenol. 1997;168:1357–1360
  185. Boland GW, Goldberg MA, Lee MJ, et al. Indeterminate adrenal mass in patients with cancer: Evaluation at PET with 2-[F-18]-fluoro-2-deoxy-d-glucose. Radiology. 1995;194:131–134
  186. Maurea S, Klain M, Mainolfi C, et al. The diagnostic role of radionuclide imaging in evaluation of patients with nonhypersecreting adrenal masses. J Nucl Med. 2001;42:884–892
  187. Maurea S, Mainolfi C, Bazzicalupo L, et al. Imaging of adrenal tumors using FDG PET: Comparison of benign and malignant lesions. AJR Am J Roentgenol. 1999;173:25–29
  188. Tsushima Y, Ishizaka H, Matsumoto M. Adrenal masses: Differentiation with chemical shift, fast low-angle shot MR imaging. Radiology. 1993;186:705–709
  189. Hustinx R, Paulus P, Jacquet N, et al. Clinical evaluation of whole-body 18F-fluorodeoxyglucose positron emission tomography in the detection of liver metastases. Ann Oncol. 1998;9:397–401
  190. Huebner RH, Park KC, Shepherd JE, et al. A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer. J Nucl Med. 2000;41:1177–1189
  191. Delbeke D, Martin WH, Sandler MP, et al. Evaluation of benign vs malignant hepatic lesions with positron emission tomography. Arch Surg. 1998;133:510–515
  192. Erasmus JJ, McAdams HP, Rossi SE, et al. FDG PET of pleural effusions in patients with non-small cell lung cancer. AJR Am J Roentgenol. 2000;175:245–249
  193. Carretta A, Landoni C, Melloni G, et al. 18-FDG positron emission tomography in the evaluation of malignant pleural diseases—A pilot study. Eur J Cardiothorac Surg. 2000;17:377–383
  194. Weng E, Tran L, Rege S, et al. Accuracy and clinical impact of mediastinal lymph node staging with FDG-PET imaging in potentially resectable lung cancer. Am J Clin Oncol. 2000;23:47–52
  195. Kalff VV, Hicks RJ, MacManus MP, et al. Clinical impact of (18)F fluorodeoxyglucose positron emission tomography in patients with non-small-cell lung cancer: A prospective study. J Clin Oncol. 2001;19:111–118
  196. Van Tinteren H, Hoekstra O, Smit E, et al: Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial Lancet 359: 1388–92
  197. Gambhir SS, Hoh CK, Phelps ME, et al. Decision tree sensitivity analysis for cost-effectiveness of FDG-PET in the staging and management of non-small-cell lung carcinoma. J Nucl Med. 1996;37:1428–1436
  198. Scott WJ, Shepherd J, Gambhir SS. Cost-effectiveness of FDG-PET for staging non-small cell lung cancer: A decision analysis. Ann Thorac Surg. 1998;66:1876–1883
  199. Garber AM, Phelps CE. Economic foundations of costeffectiveness analysis: Working papers series. Natl Bur Econ Res. 1992;4164:1–34
  200. Kosuda S, Ichihara K, Watanabe M, et al. Decision-tree sensitivity analysis for cost-effectiveness of chest 2-fluoro-2-d-[(18)F]fluorodeoxyglucose positron emission tomography in patients with pulmonary nodules (non-small cell lung carcinoma) in Japan. Chest. 2000;117:346–353
  201. Valk PE, Pounds TR, Tesar RD, et al. Cost-effectiveness of PET imaging in clinical oncology. Nucl Med Biol. 1996;23:737–743
  202. Miles KA. An approach to demonstrating cost-effectiveness of diagnostic imaging modalities in Australia illustrated by positron emission tomography. Australas Radiol. 2001;45:9–18
  203. Inou T, Kim EE, Komaki R, et al. Detecting recurrent or residual lung cancer with FDG-PET. J Nucl Med. 1995;36:788–793
  204. Kubota K, Yamada S, Ishiwata K, et al. Positron emission tomography for treatment evaluation and recurrence detection compared with CT in long-term follow-up cases of lung cancer. Clin Nucl Med. 1992;17:877–881
  205. Patz EF, Lowe VJ, Hoffman JM, et al. Persistent or recurrent bronchogenic carcinoma: Detection with PET and 2-[F-18]-2-deoxy-d-glucose. Radiology. 1994;191:379–382
  206. Hebert ME, Lowe VJ, Hoffman JM, et al. Positron emission tomography in the pretreatment evaluation and follow-up of non-small cell lung cancer patients treated with radiotherapy: Preliminary findings. Am J Clin Oncol. 1996;19:416–421
  207. Frank A, Lefkowitz D, Jaeger S, et al. Decision logic for retreatment of asymptomatic lung cancer recurrence based on positron emission tomography findings. Int J Radiat Oncol Biol Phys. 1995;32:1495–1512
  208. Bury T, Corhay JL, Duysinx B, et al. Value of FDG-PET in detecting residual or recurrent nonsmall cell lung cancer. Eur Respir J. 1999;14:1376–1380
  209. Dunagan D, Chin R, McCain T, et al. Staging by positron emission tomography predicts survival in patients with non-small cell lung cancer. Chest. 2001;119:333–339
  210. Dhital K, Saunders CA, Seed PT, et al. [(18)F]Fluorordeoxyglucose positron emission tomography and its prognostic value in lung cancer. Eur J Cardiothorac Surg. 2000;18:425–428
  211. Ahuja V, Coleman RE, Herndon J, et al. The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with nonsmall cell lung carcinoma. Cancer. 1998;83:918–924
  212. Vansteenkiste JF, Stroobants SG, Dupont PJ, et al. Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: An analysis of 125 cases. Leuven Lung Cancer Group. J Clin Oncol. 1999;17:3201–3206
  213. Patz EF, Connolly J, Herndon J. Prognostic value of thoracic FDG PET imaging after treatment for non-small cell lung cancer. AJR Am J Roentgenol. 2000;174:769–774
  214. Vesselle H, Schmidt RA, Pugsley JM, et al. Lung cancer proliferation correlates with [F-18]fluorodeoxyglucose uptake by positron emission tomography. Clin Cancer Res. 2000;6:3837–3844
  215. Stanley KE. Prognostic factors for survival in patients with inoperable lung cancer. J Natl Cancer Inst. 1980;65:25–32
  216. Younes M, Brown RW, Stephenson M, et al. Overexpression of Glut1 and Glut3 in stage I nonsmall cell lung carcinoma is associated with poor survival. Cancer. 1997;80:1046–1051
  217. Minn H, Kangas L, Kellokumpu-Lehtinen P, et al. Uptake of 2-fluoro-2-deoxy-d-[U-14C]-glucose during chemotherapy in murine Lewis lung tumor. Int J Rad Appl Instrum B. 1992;19:55–63
  218. Abe Y, Matsuzawa T, Fujiwara T, et al. Clinical assessment of therapeutic effects on cancer using 18F-2-fluoro-2-deoxy-d-glucose and positron emission tomography: Preliminary study of lung cancer. Int J Radiat Oncol Biol Phys. 1990;19:1005–1010
  219. Vansteenkiste JF, Stroobants SG, De Leyn PR, et al. Potential use of FDG-PET scan after induction chemotherapy in surgically staged IIIa-N2 non-small-cell lung cancer: A prospective pilot study. The Leuven Lung Cancer Group. Ann Oncol. 1998;9:1193–1198
  220. Akhurst T, Downey RJ, Ginsberg MS, et al. An initial experience with FDG-PET in the imaging of residual disease after induction therapy for lung cancer. Ann Thorac Surg. 2002;73:259–264
  221. Ryu JS, Choi NC, Fischman AJ, et al. FDG-PET in staging and restaging non-small cell lung cancer after neoadjuvant chemoradiotherapy: Correlation with histopathology. Lung Cancer. 2002;35:179–187
  222. Dehdashti F, Flanagan FL, Mortimer JE, et al. Positron emission tomographic assessment of “metabolic flare” to predict response of metastatic breast cancer to antiestrogen therapy. Eur J Nucl Med. 1999;26:51–56
  223. Romer W, Hanauske AR, Ziegler S, et al. Positron emission tomography in non-Hodgkin's lymphoma: Assessment of chemotherapy with fluorodeoxyglucose. Blood. 1998;91:4464–4471
  224. Mikhaeel NG, Timothy A, O'Doherty MJ, et al. 18-FDG-PET as a prognostic indicator in the treatment of suggestive non-Hodgkin's lymphoma—Comparison with CT. Leuk Lymphoma. 2000;39:543–553
  225. Weber WA, Ott K, Becker K, et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol. 2001;19:3058–3065
  226. Spaepen K, Stroobants S, Dupont P, et al. Can positron emission tomography with [18F]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity?. Br J Haematol. 2001;115:272–278
  227. Ichiya Y, Kuwabara Y, Sasaki M, et al. A clinical evaluation of FDG-PET to assess the response in radiation therapy for bronchogenic carcinoma. Ann Nucl Med. 1996;10:193–200
  228. Kubota K, Yamada S, Ishiwata K, et al. Evaluation of the treatment response of lung cancer with positron emission tomography and l-[methyl-11C]methionine: A preliminary study. Eur J Nucl Med. 1993;20:495–501
  229. O'Doherty MJ. PET in oncology. I—Lung, breast, soft tissue sarcoma. Nucl Med Commun. 2000;21:224–229
  230. Vanuytsel LJ, Vansteenkiste JF, Stroobants SG, et al. The impact of (18)F-fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) lymph node staging on the radiation treatment volumes in patients with non-small cell lung cancer. Radiother Oncol. 2000;55:317–324
  231. Kiffer JD, Berlangieri SU, Scott AM, et al. The contribution of 18F-fluoro-2-deoxy-glucose positron emission tomographic imaging to radiotherapy planning in lung cancer. Lung Cancer. 1998;19:167–177
  232. Munley MT, Marks LB, Scarfone C, et al. Multimodality nuclear medicine imaging in three-dimensional radiation treatment planning for lung cancer: Challenges and prospects. Lung Cancer. 1999;23:105–114
  233. Nestle U, Walter K, Schmidt S, et al. 18F-Deoxyglucose positron emission tomography (FDG-PET) for the planning of radiotherapy in lung cancer: High impact in patients with atelectasis. Int J Radiat Oncol Biol Phys. 1999;44:593–597
  234. Giraud P, Grahek D, Montravers F, et al. CT and (18)F-deoxyglucose (FDG) image fusion for optimization of conformal radiotherapy of lung cancers. Int J Radiat Oncol Biol Phys. 2001;49:1249–1257
  235. Mac Manus MP, Hicks RJ, Matthews JP, et al. High rate of detection of unsuspected distant metastases by PET in apparent stage III non-small-cell lung cancer: Implications for radical radiation therapy. Int J Radiat Oncol Biol Phys. 2001;50:287–293
  236. Schumacher T, Brink I, Mix M, et al. FDG-PET imaging for the staging and follow-up of small cell lung cancer. Eur J Nucl Med. 2001;28:483–488
  237. Hauber HP, Bohuslavizki KH, Lund CH, et al: Positron emission tomography in the staging of small-cell lung cancer: A preliminary study Chest 119: 950–954
  238. Crotty E, Patz EF. FDG-PET imaging in patients with paraneo-plastic syndromes and suspected small cell lung cancer. J Thorac Imaging. 2001;16:89–93
  239. Rees JH, Hain SF, Johnson MR, et al. The role of [(18)F]fluoro-2-deoxyglucose-PET scanning in the diagnosis of paraneoplastic neurological disorders. Brain. 2001;124:2223–2231
  240. Ellis SM, Husband JE, Armstrong P, et al. Computed tomography screening for lung cancer: Back to basics. Clin Radiol. 2001;56:691–699
  241. Munden RF, Hess KR. “Ditzels” on chest CT: Survey of members of the Society of Thoracic Radiology. AJR Am J Roentgenol. 2001;176:1363–1369
  242. Ginsberg MS, Griff SK, Go BD, et al. Pulmonary nodules resected at video-assisted thoracoscopic surgery: Etiology in 426 patients. Radiology. 1999;213:277–282
  243. Lowe VJ, DeLong DM, Hoffman JM, et al. Optimum scanning protocol for FDG-PET evaluation of pulmonary malignancy. J Nucl Med. 1995;36:883–887
  244. Hamberg LM, Hunter GJ, Alpert NM, et al. The dose uptake ratio as an index of glucose metabolism: Useful parameter or oversimplification?. J Nucl Med. 1994;35:1308–1312
  245. Kubota K, Itoh M, Ozaki K, et al. Advantage of delayed whole-body FDG-PET imaging for tumour detection. Eur J Nucl Med. 2001;28:696–703
  246. Lodge MA, Lucas JD, Marsden PK, et al. A PET study of 18FDG uptake in soft tissue masses. Eur J Nucl Med. 1999;26:22–30
  247. Mastin ST, Drane WE, Harman EM, et al. FDG SPECT in patients with lung masses. Chest. 1999;115:1012–1017
  248. Kim S, Park CH, Han M, et al. The clinical usefulness of F-18 FDG coincidence PET without attenuation correction and without wholebody scanning mode in pulmonary lesions comparison with CT, MRI, and clinical findings. Clin Nucl Med. 1999;24:945–949
  249. Roman MR, Rossleigh MA, Angelides S, et al. Staging and managing lung tumors using F-18 FDG coincidence detection. Clin Nucl Med. 2001;26:383–388
  250. Stokkel MP, Bakker PF, Heine R, et al. Staging of lymph nodes with FDG dual-headed PET in patients with non-small-cell lung cancer. Nucl Med Commun. 1999;20:1001–1007
  251. Tatsumi M, Yutani K, Watanabe Y, et al. Feasibility of fluorode-oxyglucose dual-head gamma camera coincidence imaging in the evaluation of lung cancer: Comparison with FDG PET. J Nucl Med. 1999;40:566–573
  252. Weber WA, Neverve J, Sklarek J, et al. Imaging of lung cancer with fluorine-18 fluorodeoxyglucose: Comparison of a dual-head gamma camera in coincidence mode with a full-ring positron emission tomography system. Eur J Nucl Med. 1999;26:388–395
  253. Bury T, Dowlati A, Paulus P, et al. Evaluation of the solitary pulmonary nodule by positron emission tomography imaging. Eur Respir J. 1996;9:410–414
  254. Pitman AG, Hicks RJ, Kalff V, et al. Positron emission tomography in pulmonary masses where tissue diagnosis is unhelpful or not possible. Med J Aust. 2001;175:303–307
  255. Hicks RJ, Kalff V, MacManus MP, et al. 18F-FDG PET provides high-impact and powerful prognostic stratification in staging newly diagnosed non-small cell lung cancer. J Nucl Med. 2001;42:1596–1604
  256. Ak I, Blockland JA, Pauwels EK, et al. The clinical value of 18F-FDG detection with a dual-head coincidence camera: A review. Eur J Nucl Med. 2001;28:763–778
  257. Vansteenkiste JF, Stroobants SG, De Leyn PR, et al. Mediastinal lymph node staging with FDG-PET scan in patients with potentially operable non-small cell lung cancer: A prospective analysis of 50 cases. Leuven Lung Cancer Group. Chest. 1997;122:1480–1486
  258. Magnani P, Carretta A, Rizzo G, et al. FDG/PET and spiral CT image fusion for mediastinal lymph node assessment of non-small cell lung cancer patients. J Cardiovasc Surg (Torino). 1999;40:741–748
  259. Rueckert D, Sonoda LI, Hayes C, et al. Nonrigid registration using free-form deformations: Application to breast MR images. IEEE Trans Med Imaging. 1999;18:712–721
  260. Goerres GW, Kamel E, Heidelberg TN, et al. PET-CT image co-registration in the thorax: Influence of respiration. Eur J Nucl Med. 2002;29:351–360
  261. Kinahan PE, Townsend DW, Beyer T, et al. Attenuation correction for a combined 3D PET/CT scanner. Med Phys. 1998;25:2046–2053
  262. Kamel E, Hany TF, Burger C, et al. CT va (68)Ge attenuation correction in a combined PET/CT system: Evaluation of the effect of lowering the CT tube current. Eur J Nucl Med. 2002;29:346–350
  263. Busch H, Davis J, Honig G, et al. The uptake of a variety of amino acids into nuclear proteins of tumors and other tissues. Cancer Res. 1959;19:1030–1039
  264. Isselbacher KJ. Sugar and amino acid transport by cells in culture—differences between normal and malignant cells. N Engl J Med. 1972;286:929–933
  265. Inoue T, Kim EE, Wong FC, et al. Comparison of fluorine-18-fluorodeoxyglucose and carbon-11-methionine PET in detection of malignant tumors. J Nucl Med. 1996;37:1472–1476
  266. Nettelbladt OS, Sundin AE, Valind SO, et al. Combined fluorine-18-FDG and carbon-11-methionine PET for diagnosis of tumors in lung and mediastinum. J Nucl Med. 1998;39:640–647
  267. Yasukawa T, Yoshikawa K, Aoyagi H, et al. Usefulness of PET with 11C-methionine for the detection of hilar and mediastinal lymph node metastasis in lung cancer. J Nucl Med. 2000;41:283–290
  268. Miyazawa H, Arai T, Iio M, et al. PET imaging of non-small-cell lung carcinoma with carbon-11-methionine: Relationship between radio-activity uptake and flow-cytometric parameters. J Nucl Med. 1993;34:1886–1891
  269. Kubota R, Yamada S, Kubota K, et al. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: High accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med. 1992;33:1972–1980
  270. Inoue T, Koyama K, Oriuchi N, et al. Detection of malignant tumors: Whole-body PET with fluorine 18 alpha-methyl tyrosine versus FDG—Preliminary study. Radiology. 2001;220:54–62
  271. Jager PL, Groen HJ, van der Leest A, et al. l-3-[123I]Iodo-alphamethyl-tyrosine SPECT in non-small cell lung cancer: Preliminary observations. J Nucl Med. 2001;42:579–585
  272. Tewson TJ, Krohn KA. PET radiopharmaceuticals: State-of-the-art and future prospects. In: Semin Nucl Med. 28:1998;p. 221–234
  273. Shields AF, Grierson JR, Dohmen BM, et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med. 1998;4:1334–1336
  274. Hustinx R, Eck SL, Alavi A. Potential applications of PET imaging in developing novel cancer therapies. J Nucl Med. 1999;40:995–1002
  275. Rasey JS, Koh WJ, Evans ML, et al. Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole: A pretherapy study of 37 patients. Int J Radiat Oncol Biol Phys. 1996;36:417–428
  276. Lehtio K, Oikonen V, Gronroos T, et al. Imaging of blood flow and hypoxia in head and neck cancer: Initial evaluation with [(15)O]H(2)O and [(18)F]fluoroerythronitroimidazole PET. J Nucl Med. 2001;42:1643–1652
  277. Lewis JS, Sharp TL, Laforest R, et al. Tumor uptake of copperdiacetyl-bis(N(4)-methylthiosemicarbazone): Effect of changes in tissue oxygenation. J Nucl Med. 2001;42:655–661
  278. Flower MA, Zweit J, Hall AD, et al. 62Cu-PTSM and PET used for the assessment of angiotensin II-induced blood flow changes in patients with colorectal liver metastases. Eur J Nucl Med. 2001;28:99–103
  279. Lewis JS, McCarthy DW, McCarthy TJ, et al. Evaluation of 64Cu-ATSM in vitro and in vivo in a hypoxic tumor model. J Nucl Med. 1999;40:177–183
  280. Dearling J, Lewis J, McCarthy D, et al. Redox-active metal complexes for imaging hypoxic tissues: Structure activity relationships in copper(II) bis(thiosemicarbazone) complexes. Chem Commun. 1998;22:2531–2532
  281. Dearling JLJ, Lewis JS, Mullen GED, et al: Copper bis(thiosemicarbazone) complexes as hypoxia imaging agents: Structure-activity relationships. J Biol Inorg Chem (in press)
  282. Haubner R, Wester HJ, Weber WA, et al. Noninvasive imaging of alpha(v)beta3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res. 2001;61:1781–1785
  283. Rom WN, Hay JG, Lee TC, et al. Molecular and genetic aspects of lung cancer. Am J Respir Crit Care Med. 2000;161:1355–1367
  284. Phelps ME. Inaugural article: Positron emission tomography provides molecular imaging of biological processes. In: Proc Natl Acad Sci USA. 97:2000;p. 9226–9233
  285. Sazon DA, Santiago SM, Soo Hoo GW, et al. Fluorodeoxyglucosepositron emission tomography in the detection and staging of lung cancer. Am J Respir Crit Care Med. 1996;153:417–421
  286. Guhlmann A, Storck M, Kotzerke J, et al. Lymph node staging in non-small cell lung cancer: Evaluation by [18F]FDG positron emission tomography (PET). Thorax. 1997;52:438–441
  287. Hagberg RC, Segall GM, Stark P, et al. Characterization of pulmonary nodules and mediastinal staging of bronchogenic carcinoma with F-18 fluorodeoxyglucose positron emission tomography. Eur J Cardiothorac Surg. 1997;12:92–97
  288. Shreve PD, Steventon RS, Deters EC, et al. Oncologic diagnosis with 2-[fluorine-18]fluoro-2-deoxy-d-glucose imaging: Dual-head coincidence gamma camera versus positron emission tomographic scanner. Radiology. 1998;207:431–437
  289. Albes JM, Lietzenmayer R, Schott U, et al. Improvement of non-small-cell lung cancer staging by means of positron emission tomography. Thorac Cardiovasc Surg. 1999;47:42–47
  290. Collins BT, Lowe VJ, Dunphy FR. Initial evaluation of pulmonary abnormalities: CT-guided fine-needle aspiration biopsy and fluoride-18 fluorodeoxyglucose positron emission tomography correlation. Diagn Cytopathol. 2000;22:92–96
  291. Lewis PJ, Salama A. Uptake of fluorine-18-fluorodeoxyglucose in sarcoidosis. J Nucl Med. 1994;35:1647–1649
  292. Lonneux M, Delval D, Bausart R, et al. Can dual-headed 18F-FDG SPET imaging reliably supersede PET in clinical oncology? A comparative study in lung and gastrointestinal tract cancer. Nucl Med Commun. 1998;19:1047–1054
  293. Roberts PF, Follette DM, von Haag D, et al. Factors associated with false-positive staging of lung cancer by positron emission tomography. Ann Thorac Surg. 2000;70:1154–1159
  294. Gupta NC, Graeber GM, Rogers JS, et al. Comparative efficacy of positron emission tomography with FDG and computed tomographic scanning in preoperative staging of non-small cell lung cancer. Ann Surg. 1999;229:286–291
  295. Kernstine KH, Stanford W, Mullan BF, et al. PET, CT, and MRI with Combidex for mediastinal staging in non-small cell lung carcinoma. Ann Thorac Surg. 1999;68:1022–1028
  296. Gupta NC, Tamim WJ, Graeber CG, et al. Mediastinal lymph node sampling following positron emission tomography with fluorodeoxyglucose imaging in lung cancer staging. Chest. 2001;120:521–527
  297. Brudin LH, Valind SO, Rhodes CG, et al. Fluorine-18 deoxyglucose uptake in sarcoidosis measured with positron emission tomography. Eur J Nucl Med. 1994;21:297–305
  298. Bury T, Dowlati A, Paulus P, et al. Staging of non-small-cell lung cancer by whole-body fluorine-18 deoxyglucose positron emission tomography. Eur J Nucl Med. 1996;23:204–206

PII: S0001-2998(02)80017-4

doi: 10.1053/snuc.2002.126059

Seminars in Nuclear Medicine
Volume 32, Issue 4 , Pages 240-271 , October 2002

Article Tools